chufangao/CTO huggingface dataset:
Clinical trial NCT04248153: Optimal Timing of BR55 CEUS of the Ovaries
Official title: An Exploratory Study to Determine the Optimal Timing of BR55 Contrast Enhanced Ultrasound (CEUS) of the Ovaries in Pre-menopausal Women
Sponsor: Bracco Diagnostics, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision; expiration of available study agent due to long recruitment timeline.
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-14
Primary completion date: 2020-02-19
Completion date: 2021-07-31
Baseline population: The only participants enrolled in this study were 3 training cases. No other study participant was enrolled in the study; therefore, there are no results for Group A and Group B.
Plan to share individual participant data: NO
Clinical trial NCT04434378: Tamsulosin to Prevent Postoperative Urinary Retention in Laparoscopic Inguinal Hernia Repair
Official title: The Use of Tamsulosin to Prevent Postoperative Urinary Retention in Laparoscopic Inguinal Hernia Repair: A Randomized Double-Blind Placebo-Controlled Study
Sponsor: Jewish Hospital, Cincinnati, Ohio (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Significant difference not reached on interim analysis
Enrollment: 170.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-16
Primary completion date: 2020-02-05
Completion date: 2020-02-05
Plan to share individual participant data: NO
Clinical trial NCT03373669: Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine
Official title: Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine
Sponsor: Johns Hopkins Bloomberg School of Public Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-16
Primary completion date: 2019-10-16
Completion date: 2020-12-01
Clinical trial NCT05437848: Chinese Multiple Dose Escalation (MDE) High Dose Study
Official title: A Phase 1 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Cotadutide in Chinese Overweight/Obese Subjects With Type 2 Diabetes Mellitus
Acronym: COTA China PK
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-02-25
Primary completion date: 2022-12-12
Completion date: 2022-12-12
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.~All request will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT05645887: Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure.
Official title: Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure.
Acronym: ALBUMIM
Sponsor: Albimmune SL (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Internal reorganisations and lack of funding by the sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-02-29
Primary completion date: 2024-05-23
Completion date: 2024-05-23
Clinical trial NCT03208179: Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa
Official title: IPTp With Dihydroartemisinin-piperaquine and Azithromycin for Malaria, Sexually Transmitted and Reproductive Tract Infections in Pregnancy in High Sulphadoxine-pyrimethamine Resistance Areas in Kenya, Malawi and Tanzania
Acronym: IMPROVE
Sponsor: Liverpool School of Tropical Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 4680.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-03-29
Primary completion date: 2020-03-15
Completion date: 2020-03-15
Plan to share individual participant data: YES
IPD sharing description: Individual, de-identified participant data will be made available for meta-analyses as soon as the data analysis is completed, with the understanding that results of the meta-analysis will not be published prior to the results of the individual trial without prior agreement of the investigators. No later than 5 years after the publication of the trial a fully de-identified data set will be available for sharing purposes
IPD time frame: No later than 5 years after publication
IPD access criteria: Open access
Clinical trial NCT03315052: Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
Official title: Budesonide in Liver Transplantation
Acronym: BILT
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Delay in IRB approval
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-31
Primary completion date: 2021-01-31
Completion date: 2022-01-31
Plan to share individual participant data: UNDECIDED
IPD sharing description: Annonymous IPD will be shared in the event that the study protocol is approved at other transplanting institutions who then collaborate in this study. IPD will include standard clinical and laboratory data monitored after liver transplantation
Clinical trial NCT02718300: A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Official title: A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
Enrollment: 74.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-02-08
Primary completion date: 2021-01-28
Completion date: 2022-04-29
Baseline population: Due to early termination of the study, per the Statistical Analysis Plan, participants were combined into arms based on the dosage received regardless of what phase of the study they participated in.
Clinical trial NCT04650854: A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
Official title: An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
Sponsor: UCB Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 165.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-03
Primary completion date: 2024-01-25
Completion date: 2024-01-25
Plan to share individual participant data: YES
IPD sharing description: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Clinical trial NCT02775903: An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
Official title: A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 213.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-03
Primary completion date: 2018-12-31
Completion date: 2021-12-27
Baseline population: All randomized participants (intent-to-treat population)
Limitations and caveats: Protocol Amendment 03 was introduced on 05 Mar 2019. At the Investigator's discretion, participants meeting all the continuation criteria were eligible to enter the optional extension phase to continue to benefit from treatment with subcutaneous azacitidine and/or durvalumab. Participants started the extension phase at the time of their next regularly scheduled dosing cycle for study drug azacitidine or azacitidine and durvalumab.
Clinical trial NCT04074837: Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers
Official title: Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age
Sponsor: Neuronascent, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 56.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-08-01
Primary completion date: 2021-07-31
Completion date: 2021-08-15
Plan to share individual participant data: NO
IPD sharing description: This clinical trial will be available for peer-reviewed publication.
Clinical trial NCT02793128: The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study
Official title: A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of UGN-101 on Ablation of Upper Urinary Tract Urothelial Carcinoma
Acronym: Olympus
Sponsor: UroGen Pharma Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 71.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-04
Primary completion date: 2019-04-05
Completion date: 2020-03-05
Plan to share individual participant data: NO
Clinical trial NCT04836494: A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia
Official title: A First-in-human, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Escalation to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBP-671 in Healthy Subjects and In Patients With Propionic Acidemia or Methylmalonic Acidemia
Sponsor: CoA Therapeutics, Inc., a BridgeBio company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Slow recruitment
Enrollment: 79.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-03-25
Primary completion date: 2023-11-20
Completion date: 2023-11-20
Plan to share individual participant data: NO
Clinical trial NCT03671590: Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Official title: A Phase 1 Pharmacokinetic and Pharmacodynamic Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Sponsor: TG Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Strategic/Business Decision
Enrollment: 172.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-09-10
Primary completion date: 2024-05-21
Completion date: 2024-05-21
Plan to share individual participant data: NO
Clinical trial NCT04199598: Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.
Official title: An Open-label, Single-center, Randomized, 4-period, Single Dose, Crossover Study to Assess the Relative Bioavailability of Abediterol Inhaled Via Two Different Nebulizers and Via Dry Powder Inhaler in Healthy Subjects.
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The decision to terminate has been taken by the Sponsor. The decision is not due to safety concerns but reflects business prioritizations of the company.
Enrollment: 25.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-01-28
Primary completion date: 2020-04-03
Completion date: 2020-04-03
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT03800472: A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases
Official title: A Phase I, Randomized, Double-blind, Placebo-controlled, Single-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Including the Effect of Food, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG3312, in Adult, Healthy Subjects
Sponsor: Galapagos NV (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 95.0 (ACTUAL)
Number of arms: 9.0
Start date: 2019-01-15
Primary completion date: 2020-03-10
Completion date: 2020-03-10
Clinical trial NCT04745832: Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Official title: A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non Hodgkin's Lymphoma (iNHL) - The COASTAL Study
Sponsor: MEI Pharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Discontinuation of zandelisib program
Enrollment: 82.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-13
Primary completion date: 2023-03-20
Completion date: 2023-03-20
Plan to share individual participant data: NO
Clinical trial NCT02846376: Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
Official title: Phase I Study of Single-agent and Combined Checkpoint Inhibition After Allogeneic Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Acronym: CPIT-002
Sponsor: Hackensack Meridian Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of Enrollment
Enrollment: 8.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-08
Primary completion date: 2023-12-21
Completion date: 2023-12-21
Plan to share individual participant data: NO
Clinical trial NCT02593045: Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
Official title: Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
Sponsor: Innate Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 44.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-10-31
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Clinical trial NCT04854642: A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers
Official title: Influence of Food on the Oral Bioavailability of Ladarixin 200 mg Capsule in Healthy Volunteers of Both Sexes. A Single Dose (400 mg), Randomized, Open Label, Two-Way Crossover Study
Sponsor: Dompé Farmaceutici S.p.A (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 36.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-20
Primary completion date: 2020-12-09
Completion date: 2020-12-09
Baseline population: Enrolled set: all enrolled subjects. This analysis set was used for demographic, baseline and background characteristics
Limitations and caveats: Limitations and Caveats not specified.
Plan to share individual participant data: NO
Clinical trial NCT04950114: An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
Official title: An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
Sponsor: Goldfinch Bio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 31.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-07-27
Primary completion date: 2022-11-02
Completion date: 2022-11-02
Plan to share individual participant data: NO
Clinical trial NCT04470908: The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males
Official title: A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effect of the Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Male Subjects
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-07-29
Primary completion date: 2020-11-10
Completion date: 2020-11-10
Plan to share individual participant data: YES
Clinical trial NCT05708690: Topical Effect of Tranexamic Acid in Postoperative Bleeding and Blood Products Transfusion After Cardiac Surgery
Official title: Topical Application Effect of Tranexamic Acid in Postoperative Bleeding and Blood Products Transfusion After Cardiac Surgery
Sponsor: Indonesia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 132.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-01
Primary completion date: 2022-12-31
Completion date: 2023-01-06
Plan to share individual participant data: YES
IPD sharing description: the study protocol, ethical clearance letter, the primary database of the study, as well as the study's analysis plan and the manuscript of the study will be made available on the permission by the grant provider and ethical committee
IPD time frame: January 6, 2022 for 2 (two) years
IPD access criteria: for peer-reviewing or for further analysis or when needed by authors of a systematic review/meta analysis of randomized controlled trials
Clinical trial NCT04080076: Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy
Official title: A Multicenter Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy
Acronym: FACT
Sponsor: NephroNet, Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Study was updated and issued a new NCT number.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-12
Primary completion date: 2024-09-06
Completion date: 2024-09-06
Plan to share individual participant data: NO
Clinical trial NCT04231318: Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain
Official title: A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee
Sponsor: Anika Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 231.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-09-11
Primary completion date: 2022-05-16
Completion date: 2022-05-16
Limitations and caveats: There were no limitations or caveats associated with the conduct of this trial.
Plan to share individual participant data: NO
Clinical trial NCT03126812: Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
Official title: Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian Cancer
Sponsor: The Netherlands Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-11-01
Primary completion date: 2023-06-01
Completion date: 2024-03-05
Plan to share individual participant data: UNDECIDED
IPD sharing description: to be determinated
Clinical trial NCT02876640: Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer
Official title: Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Inadequate Accrual Rate
Enrollment: 27.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-16
Primary completion date: 2022-06-03
Completion date: 2022-06-03
Clinical trial NCT04698850: Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
Official title: Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation - Prospective Randomised Study
Acronym: BEY-RAP
Sponsor: Faculty Hospital Kralovske Vinohrady (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: funding issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-04
Primary completion date: 2023-01-31
Completion date: 2023-06-30
Plan to share individual participant data: NO